Loading organizations...
Chase Therapeutics: Specialty pharmaceutical company discovering and advancing treatments for brain diseases, including Alzheimer’s and Parkinson’s.
Washington, DC-based Chase Therapeutics is a specialty pharmaceutical company focused on developing treatments for severe neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s diseases. The biopharmaceutical firm discovers and advances novel therapeutics aimed at preventing and curing complex neuropsychiatric conditions, including improved symptomatic treatments for affected patients. Operating through a venture-funded business model, the organization has raised a total of $25.3 million in equity financing to date, which includes a $21 million Series B round and a separate $20 million funding tranche secured approximately three years ago. To support its clinical pipeline, which features a Phase 2 trial for a Pramipexole and Aprepitant combination therapy, the executive team leverages prior leadership experience from Sanofi, Roche, Otsuka, and the National Institute of Neurological Disorders and Stroke. Chase Therapeutics was founded in 2017 by Thomas Chase and Kathleen Clarence-Smith.
Chase Therapeutics has raised $20.0M across 1 funding round.
Chase Therapeutics has raised $20.0M in total across 1 funding round.
Chase Therapeutics has raised $20.0M in total across 1 funding round.
Chase Therapeutics's investors include Javier Romero, Brain Trust Accelerator Fund II, Makana Holdings, Rise of the Rest.
Chase Therapeutics has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series B in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 20, 2021 | $20.0M Series B | Javier Romero | Brain Trust Accelerator Fund II, Makana Holdings, Rise of the Rest |